Page 2 - Indigo System News Today

Shares of Penumbra, Inc. (NYSE:PEN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the nine research firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month […]

Shares of Penumbra, Inc. (NYSE:PEN – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among analysts […]

Founded in 2004, Penumbra has grown into a global healthcare company specializing in innovative therapies. With over 4000 employees, the company offers products in more than 100 markets worldwide....

Penumbra, Inc. (NYSE:PEN – Get Free Report) Director Don W. Kassing sold 170 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $223.18, for a total transaction of $37,940.60. Following the completion of the transaction, the director now directly owns 1,175 shares in the […]

Penumbra, Inc. (NYSE:PEN – Get Free Report) Director Don W. Kassing sold 170 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $223.18, for a total value of $37,940.60. Following the completion of the sale, the director now directly owns 1,175 shares in […]

Shares of Penumbra, Inc. (NYSE:PEN – Get Free Report) have earned an average rating of “Moderate Buy” from the nine ratings firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year […]

Shares of Penumbra, Inc. (NYSE:PEN – Get Free Report) have been assigned an average rating of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price […]

Penumbra’s Indigo System CAT RX allows healthcare professionals to remove blood clots from the coronary & peripheral vasculature

Latest technology combines superior catheter design and sustained aspiration to maximize blood clot removal from the coronary vasculature

The latest STRIKE-PE data, presented by Penumbra, Inc. at the Vascular Interventional Advances Conference, VIVA23, showed that computer assisted vacuum thrombectomy (CAVT) for the treatment of pulmonary embolism is safe and effective at reducing right heart strain, and also improved clinical and functional outcomes.